You are here: Industry Insights > Merck

News List

Merck launches Next-Gen Tech for intensified drug production biospectrumasia
September 06, 2018
Technologies include first-of-its-kind cation exchange (CEX) chromatography resin for flow-through removal of mAb aggregates.
Merck bags USFDA approval for 2 new HIV drugs biospectrumasia
September 05, 2018
Since the beginning of the epidemic, more than 70 million people have been infected with the HIV virus and about 35 million people have died of HIV
Rexahn, Merck Partner for Cancer contractpharma
August 22, 2018
Rexahn Pharmaceuticals has entered into a clinical trial collaboration agreement with Merck to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2 trial in patients with metastatic triple nega
Agenus Receives Second Milestone from Merck contractpharma
August 21, 2018
Agenus Inc. announced today that Merck initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration.
Eisai, Merck get FDA approval for LENVIMA capsules to treat HCC biospectrumasia
August 20, 2018
Marks second approval under Eisai-Merck global collaboration to co-develop and co-commercialize LENVIMA, following Japan in March 2018
Merck receives Australian CRISPR Nickase Patent biospectrumasia
August 17, 2018
In addition to allowing a patent application on paired nickases, the Australian Patent Office recently announced the formal grant of Merck's 2017 CRISPR integration patent, following withdrawal of four independent, anonymously filed oppositions.
Merck Awarded Australian CRISPR Nickase Patent americanpharmaceuticalreview
August 16, 2018
Merck announced the Australian Patent Office has allowed the company's patent application for the use of paired CRISPR nickases. Paired nickases represent a step in increasing safety by driving specificity through a highly flexible and efficient approach
Merck profits decline but new drugs maintain sales growth pharmatimes
August 13, 2018
Merck’s has reported a 42% decline in net income to 247 million euros ($283 million) for Q2, but new drugs Bavencio and Mavenclad helped the company maintain organic sales growth.
AstraZeneca and Merck obtain EMA orphan status for selumetinib pharmaceutical-technology
August 07, 2018
AstraZeneca and Merck (MSD) have secured the European Medicines Agency orphan designation for a MEK 1/2 inhibitor called selumetinib to treat neurofibromatosis type 1 (NF1).
Merck’s Ebola vaccine to be used in latest Congo outbreak, with a new hurdle ahead fiercepharma
August 07, 2018
The latest Ebola outbreak in the Democratic Republic of Congo will again turn to Merck & Co’s experimental rVSV-ZEBOV that was so successful in attacking the last outbreak.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page